Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.64 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10374101 | 0.87 | TP53 (0.77) | TP53ALOX12MAPTHTTSLC5A1 | |
| SCHEMBL10374929 | 0.86 | TP53 (0.75) | TP53ALOX12MAPTHTTSLC5A1 | |
| SCHEMBL1753520 | 0.86 | TP53 (0.75) | TP53ALOX12MAPTHTTSLC5A1 | |
| SCHEMBL3402296 | 0.86 | TP53 (0.75) | TP53ALOX12MAPTSLC5A1SLC5A2 | |
| SCHEMBL15882211 | 0.85 | SMN1; SMN2 (0.77) | TP53ALOX12MAPTSLC5A1SLC5A2 | |
| SCHEMBL20027621 | 0.85 | TP53 (0.73) | TP53ALOX12MAPTHTTSLC5A1 | |
| SCHEMBL17321555 | 0.83 | TP53 (0.71) | TP53ALOX12MAPTHTTSLC5A1 | |
| SCHEMBL23153554 | 0.82 | TP53 (0.70) | TP53ALOX12MAPTHTTSLC5A1 | |
| SCHEMBL3406954 | 0.82 | ALOX12 (0.69) | TP53ALOX12MAPTHTTSLC5A1 | |
| SCHEMBL28487777 | 0.81 | TP53 (0.68) | TP53ALOX12MAPTHTTSLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025261989-A1 | 1,2,3-TRIAZOLE DERIVATIVES AS IL4i1 INHIBITORS | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-12-26 | — | — | WO | disclosed |
| US-12384763-B2 | Protein and/or peptide modification molecule | OSAKA UNIVERSITY (JP) | 2025-08-12 | — | — | US | disclosed |
| WO-2024114680-A9 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | 海南先声再明医药股份有限公司 | 2024-08-15 | — | — | WO | disclosed |
| WO-2024114680-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | 海南先声再明医药股份有限公司 | 2024-06-06 | — | — | WO | disclosed |
| US-11691992-B2 | Oxaborole analogs and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691992-B2 | Oxaborole analogs and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| CN-110642837-B | Pyridine amide compound containing triazole or quinolinone structure and application thereof | 江西科技师范大学 | 2023-03-21 | — | — | CN | disclosed |
| US-20220204481-A1 | PROTEIN AND/OR PEPTIDE MODIFICATION MOLECULE | OSAKA UNIVERSITY (JP) | 2022-06-30 | — | — | US | disclosed |
| US-20220204481-A1 | PROTEIN AND/OR PEPTIDE MODIFICATION MOLECULE | OSAKA UNIVERSITY (JP) | 2022-06-30 | — | — | US | disclosed |
| EP-3932912-A1 | PROTEIN AND/OR PEPTIDE MODIFICATION MOLECULE | Osaka University (JP) | 2022-01-05 | — | — | EP | disclosed |
| US-20150353505-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-10 | — | — | US | disclosed |
| EP-2945943-A2 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | Bristol-Myers Squibb Company (US) | 2015-11-25 | — | — | EP | disclosed |
| WO-2014113620-A2 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014113620-A2 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-24 | — | — | WO | disclosed |
| US-6974813-B2 | N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia | WARNER-LAMBERT COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| JP-2005041879-A | N-[(SUBSTITUTED FIVE-MEMBERED DI-OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVE FOR TREATMENT OF ISCHEMIA | PFIZER PROD INC | 2005-02-17 | — | — | JP | disclosed |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER INC. | 2003-08-07 | — | — | US | disclosed |
| US-6492401-B1 | SODIUM HYDROGEN EXCHANGER TYPE 1 INHIBITORS; REDUCING PERIOPERATIVE MYOCARDIAL TISSUE DAMAGE | PFIZER, INC. | 2002-12-10 | — | — | US | disclosed |
| EP-1056729-A1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | Pfizer Products Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043663-A1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL] GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | PFIZER PRODUCTS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691992-B2 | Oxaborole analogs and uses thereof | OXA1L, EPX, OAT | TP53 4500/4885ALOX12 275/4885MAPT 4347/4885 |
| US-20220204481-A1 | PROTEIN AND/OR PEPTIDE MODIFICATION MOLECULE | PTMS, DNPEP, NPPA | TP53 343/4885ALOX12 4413/4885MAPT 624/4885 |
| US-20150353505-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | TP53 1789/4885ALOX12 900/4885MAPT 138/4885 |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | NHERF1, SLC28A1, TNNI3 | TP53 4706/4885ALOX12 1166/4885MAPT 4418/4885 |
| US-12384763-B2 | Protein and/or peptide modification molecule | PTMS, DNPEP, NPPA | TP53 343/4885ALOX12 4413/4885MAPT 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.